Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
Fiche du document
2010
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1128/mBio.00171-10
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/20844609
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2150-7511
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_4DFE2B779A054
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Histamine-producing cell-stimulating factor GM-CSF (Colony-stimulating factor) CSF-GM (Colony-stimulating factor) Follicular dendritic cells Interdigitating cells Antigen determinants Epitopes Antigenic determinant groups Determinants, Antigenic Epitypes Communicable diseases--Vaccination Preventive inoculation Inoculation Tumours Neoplasms Thymus-dependent lymphocytes Thymus-derived cells T lymphocytes Thymus-dependent cells LCM virus Expressive behavior Agency (Philosophy) Agents Person (Philosophy) Preventive inoculation Diseases--VaccinationCiter ce document
L. Cervantes-Barragan et al., « Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. », Serveur académique Lausannois, ID : 10.1128/mBio.00171-10
Métriques
Partage / Export
Résumé
Efficient vaccination against infectious agents and tumors depends on specific antigen targeting to dendritic cells (DCs). We report here that biosafe coronavirus-based vaccine vectors facilitate delivery of multiple antigens and immunostimulatory cytokines to professional antigen-presenting cells in vitro and in vivo. Vaccine vectors based on heavily attenuated murine coronavirus genomes were generated to express epitopes from the lymphocytic choriomeningitis virus glycoprotein, or human Melan-A, in combination with the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). These vectors selectively targeted DCs in vitro and in vivo resulting in vector-mediated antigen expression and efficient maturation of DCs. Single application of only low vector doses elicited strong and long-lasting cytotoxic T-cell responses, providing protective antiviral and antitumor immunity. Furthermore, human DCs transduced with Melan-A-recombinant human coronavirus 229E efficiently activated tumor-specific CD8(+) T cells. Taken together, this novel vaccine platform is well suited to deliver antigens and immunostimulatory cytokines to DCs and to initiate and maintain protective immunity.